Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, researchers explored the design of composite biomaterials for immunomodulation and their potential to influence immune cell behavior, which could be leveraged for treating diseases like cancer and improving tissue regeneration, while also addressing translational challenges such as biocompatibility and safety.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

This study found that locally injected zalutumumab in healthy volunteers induced a papulopustular rash similar to systemic EGFR inhibitors, and that IL-8 inhibition reduced this dermatological side effect.

In this study, older age and fewer hepatitis vaccinations were linked to lower HBV antibody responses in nursing staff, with antibody levels declining over five years, suggesting a potential need for booster doses.

In this study, imiquimod was found to increase regression of cervical intraepithelial neoplasia compared to placebo, though it commonly caused side effects that rarely led to treatment discontinuation.

This report documents the successful use of theophylline in treating an 11-year-old girl with a rare immunodeficiency syndrome, suggesting potential in drug repurposing for primary immunodeficiency disorders and asthma.

Immunosuppression therapy with methylprednisolone effectively treats childhood alopecia areata.

This case study reports that adding adalimumab to a 12-year-old VKH patient's treatment allowed for ocular inflammation remission, vision improvement, and corticosteroid tapering, suggesting escalation of immunosuppression may be critical in pediatric VKH cases.

This case study reports that immunotherapy with ipilimumab and nivolumab induced hypophysitis in a patient with renal cell carcinoma, emphasizing the need for careful monitoring of endocrine function in such treatments.

This case report describes a young adult with primary follicular mucinosis, successfully treated with topical tacrolimus, resulting in resolution without sequelae.

This review characterizes breast implant illness and its autoimmune symptoms, reporting an association between breast implants and autoimmune diseases, with explantation relieving symptoms in over half of patients.

This article compares the immunology of cancer and the placenta and suggests that immunotherapy for pregnant cancer patients could be feasible with careful exploration, though no new clinical results are reported.

This review discusses the characteristics and management of cutaneous immune-related adverse events from immune checkpoint inhibitors and notes their potential association with a favorable cancer treatment response.

This study demonstrated that a microarray patch can deliver antibodies in a controlled and prolonged manner, maintaining their functionality after manufacturing and heat exposure, with successful pharmacokinetic proof-of-concept in rats.

This review discusses the increasing reports of rare cutaneous side effects from topical imiquimod, aiming to inform physicians and dermatologists about its potential adverse effects as its use expands.

This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.

In this study, researchers observed temporary skin reactions at BCG vaccination sites following the Pfizer-BioNTech COVID-19 mRNA vaccine in five patients, suggesting underreported occurrences.

This study used a Lebanese national registry to document dermatologic symptoms related to COVID-19 and its vaccines, noting that urticaria and telogen effluvium were common during infection, while urticaria and herpes zoster were notable post-vaccination.

In this study, skin manifestations were observed in 48% of children with primary immunodeficiency disorders, often providing crucial diagnostic clues for early identification of these conditions.

This case report describes a 6-year-old girl who developed MIS-C following COVID-19 vaccination, raising questions about the vaccine's potential role in its pathogenesis for children aged 5 to 11.

The study introduced an advanced skin model, ImmuSkin-MT, which effectively distinguished between different strengths of skin sensitizers by mimicking the interaction of immune cells in skin tissue.

This study reported that intensive immunosuppression in multiple sclerosis patients significantly reduced relapse rates versus pre-treatment expectations, though some required ongoing treatment after tapering.

This case report suggests an immunological link between multifocal acquired demyelinating sensory and motor neuropathy and alopecia, with both conditions improving after treatment with intravenous immunoglobulin.

This article highlights adverse skin reactions due to injectable therapies for MS, noting that while generally mild, some cases can progress to serious lesions requiring medical intervention.

This study found that COVID-19 vaccine booster dose acceptance was high in the East Mediterranean Region, especially among those informed by the Ministry of Health, but concerns about benefits and side effects influenced rejection.

This study found no significant difference in the seroconversion rate of SARS-CoV2 IgG between patients with Immune Mediated Inflammatory diseases undergoing Targeted Immune-Modulating Therapies and those on conventional systemic treatment.

This study observed that patients receiving IL-2 immunotherapy developed a skin eruption characterized by burning and pruritus, which resolved shortly after stopping the infusion, suggesting that IL-2 mediated these effects.

This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.